Ipsen : Q1 2024 – highlights (288.70 KB)

TOTAL SALES

GROWTH PLATFORMS

NEW MEDICINES

Q1 2024	€822m
HIGHLIGHTS	+13.3%

"An excellent		Oncology
first-quarter
	Rare Disease
performance has		Neuroscience

laid a solid
foundation for		FY 2024
Ipsen's growth		GUIDANCE1
in 2024."		CONFIRMED
		Total-	Core
David Loew		sales	operating
	growth	margin
Chief Executive Officer	greater than	greater than
6.0%	30.0%
		(at constant	of
		exchange	total
		rates)	sales

+19.3%

+22.2%

€26m

€12m

+29.8%	+2.6%	€7m

GEOGRAPHIC BREAKDOWN	PIPELINE UPDATE
Q1 2024 TOTAL SALES BY REGION

33%	38%	29%	Regulatory approval and
launch of Onivyde in the
North America	Europe	Rest of World	U.S. as a first-line
			treatment for metastatic
			pancreatic ductal
			adenocarcinoma
			Two pre-clinical
			transactions

All growth rates are at constant exchange rates.

1 Excludes any impact of any additional late-stage (Phase III clinical development or later) external-innovation opportunities and incorporates expectations for Somatuline of further generic lanreotide products in the U.S & E.U - expected adverse impact of ~1%

from currencies on sales, based on average level of exchange rates in March 2024.

For further information on Ipsen's Q1 2024 sales update and definitions of financial indicators, please refer to the press release at:

www.ipsen.com/investors

Craig Marks	Nicolas Bogler
Vice President, Investor Relations	Senior Manager, Investor Relations
[phone]	[phone]
[e-mail]	[e-mail]